Neuro-oncology

Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad Scope and Implementation - A Progress Report.

Neuro-oncology

van den Bent MJ, Vogelbaum MA, Cloughesy T, Galldiks N, Albert NL, Tonn JC, Avila E, Fangusaro J, Mirsky D, Sahgal A, Soffietti R, Karschnia P, Mehta M, Kim MM, Boele F, Huse JT, Nayak L, Lim-Fat MJ, le Rhun E, Desjardins A, Lee EQ, Chukwueke U, Koekkoek JAF, Mendoza T, Loughan AR, Budhu JA, Bakas S, Huang RY, Villanueva-Meyer JE, Leone JP, Okada H, Reardon DA, Bi WL, Wen PY, Chang SM

Dual αVβ8 Integrin and PD-1 Blockade Overcomes TGFβ-Mediated B-Cell Suppression to Enhance Anti-Glioma Immunity.

Neuro-oncology

Hou D, Wang S, Castro BA, Katz JL, Dapash M, Arrieta VA, Vazquez-Cervantes GI, Wan H, Billingham LK, Du R, Murphy AR, Lopez-Rosas A, Han Y, Patel RV, Chia TY, Dmello CC, Zhang P, Sheppard D, Sonabend AM, Miska JM, Lesniak MS, Heiland DH, Lee-Chang C

Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy.

Neuro-oncology

Lin K, Zou C, Hubbard A, Sengelmann S, Goudy L, Wang IC, Sharma R, Pak J, Foster K, Ozawa T, de Groot JF, Phillips J, Vasudevan HN, Raleigh DR, Marson A, Murthy N, Gilbert LA, Berger MS, Liu SJ

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

Neuro-oncology

de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M, Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G, Rahman R, Hervey-Jumper S, Chang SM, Wen PY

EANO guideline on molecular testing of meningiomas for targeted therapy selection.

Neuro-oncology

Sahm F, Bertero L, Brandner S, Capper D, Goldbrunner R, Jenkinson MD, Kalamarides M, Lamszus K, Albert NL, Mair MJ, Berghoff AS, Mawrin C, Wirsching HG, Maas SL, Raleigh DR, Reifenberger G, Schweizer L, Suwala AK, Tabatabai G, Tabouret E, Short S, Wen PY, Weller M, Le Rhun E, Wesseling P, van den Bent M, Preusser M

Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.

Neuro-oncology

Lucas CG, Al-Adli NN, Young JS, Gupta R, Morshed RA, Wu J, Ravindranathan A, Shai A, Oberheim Bush NA, Taylor JW, de Groot J, Villanueva-Meyer JE, Pekmezci M, Perry A, Bollen AW, Theodosopoulos PV, Aghi MK, Chang EF, Hervey-Jumper SL, Raleigh DR, Molinaro AM, Costello JF, Diaz AA, Clarke JL, Butowski NA, Phillips JJ, Chang SM, Berger MS, Solomon DA

IMMU-59. AN IMMUNOSUPPRESSIVE PROGRAM ENCOMPASSING MULTIPLE IMMUNE CELL TYPES IN GBM TYPIFIED BY NOVEL MARKER LRRC25 ASSOCIATED WITH TYROBP SIGNALING.

Neuro-oncology

Daniel Zamler, Radhika Mathur, Gary Chan, Patrick Schupp, Anny Shai, Hideho Okada, Michael Oldham, Joseph Costello

EPCO-37. LONGITUDINAL TUMOR-WIDE SAMPLING OF GLIOBLASTOMA REVEALS EARLY EVOLUTIONARY DIVERGENCE OF RECURRENCE AND CLUES TOWARDS IDENTIFYING THE BIOLOGICAL TUMOR CENTER.

Neuro-oncology

Benjamin Lerman, Chibo Hong, Patrick Schupp, Lee Chen, Daniel Zamler, Ivan Smirnov, Joanna Phillips, Anny Shai, Janine Lupo, Michael Oldham, Joseph Costello

Pages